A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT07005102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT07005102
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 854 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Osimertinib (Osi) Drug
- Pemetrexed Drug
- Standard of Care Drug
- Telisotuzumab Adizutecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2, 2025
- Primary completion
- Nov 30, 2031
- Completion
- Oct 31, 2036
- Last update posted
- Apr 14, 2026
2025 – 2036
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers - Chandler II /ID# 275443 | Chandler | Arizona | 85224 | Recruiting |
| USC Norris Comprehensive Cancer Center /ID# 275343 | Los Angeles | California | 90033 | Recruiting |
| Usc Norris Oncology/Hematology Treatment Center /ID# 278673 | Newport Beach | California | 92663 | Recruiting |
| University Colorado Cancer Center /ID# 275382 | Aurora | Colorado | 80045-2517 | Recruiting |
| Mid Florida Hematology And Oncology Center /ID# 275278 | Orange City | Florida | 32763 | Recruiting |
| The Iowa Clinic /ID# 276020 | West Des Moines | Iowa | 50266 | Recruiting |
| Nho - Revive Research Institute /ID# 276115 | Lincoln | Nebraska | 68506 | Recruiting |
| Renown Regional Medical Center /ID# 276049 | Reno | Nevada | 89502 | Recruiting |
| Texas Oncology - South Austin /ID# 276033 | Austin | Texas | 78745 | Recruiting |
| The University of Texas MD Anderson Cancer Center /ID# 275107 | Houston | Texas | 77030 | Recruiting |
| Texas Oncology - Palestine Cancer Center /ID# 276034 | Palestine | Texas | 75801 | Recruiting |
| Virginia Cancer Specialists - Fairfax /ID# 275071 | Fairfax | Virginia | 22031 | Recruiting |
| University of Washington Medical Center /ID# 275866 | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07005102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07005102 live on ClinicalTrials.gov.